2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
David James Pinato, MD, MRCP, PhD, Faculty of Medicine, Department of Surgery and Cancer, NIHR Academic Clinical Lecturer, Imperial College London, discusses a study of intratumor heterogeneity in the regulation of immune-tolerogenic pathways in primary and metastatic hepatocellular carcinoma.
David James Pinato, MD, MRCP, PhD, Faculty of Medicine, Department of Surgery and Cancer, NIHR Academic Clinical Lecturer, Imperial College London, discusses a study of intratumor heterogeneity in the regulation of immune-tolerogenic pathways in primary and metastatic hepatocellular carcinoma (HCC).
Recent biomarker studies have shown that PD-1/PD-L1 targeted therapies are an efficacious systemic treatment for patients with HCC, says Pinato. PD-1 is already used as a biomarker in clinical trials, but trials in solid tumors suggest heterogeneity in PD-L1 expression in the primary metastatic population as well.
Based on this, a study was conducted to analyze PD-L1 and PD-L2 expression by immunohistochemistry. Pinato says the findings of this study may have implications for how patients are selected for immunotherapy, but that needs further research.
<<<
Related Content: